Biweekly is named as an intervention in 10 current clinical trials in our China and South Korea registers. 7 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Yun Dai Chen (2). The most-studied condition is Ischemic Stroke.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Ischemic Stroke | 2 |
| Intracranial Artery Stenosis | 1 |
| Stroke, Ischemic | 1 |
| Atherosclerosis, Cerebral | 1 |
| Myocardial Ischaemic Syndrome | 1 |
| Coronary Heart Disease | 1 |
| Large-Artery Atherosclerosis (Embolus/Thrombosis) | 1 |
| Coronary Artery Disease | 1 |
| Optical Coherence Tomography | 1 |
| Carotid Artery Stenosis | 1 |
| Acute Myocardial Infarction | 1 |
| Acute Ischemic Stroke | 1 |
| Acute Coronary Syndromes | 1 |
| Small Vessel Cerebrovascular Disease | 1 |
| Cholesterol, LDL | 1 |
| Secondary Prevention | 1 |
| Lead sponsor | Trials |
|---|---|
| Yun Dai Chen | 2 |
| Nanjing First Hospital, Nanjing Medical University | 1 |
| General Hospital of Shenyang Military Region | 1 |
| Nanjing Medical University | 1 |
| Tongji Hospital | 1 |
| First Affiliated Hospital of Xinjiang Medical University | 1 |
| Changhai Hospital | 1 |
| Nanfang Hospital, Southern Medical University | 1 |
| Seoul National University Hospital | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 9 | 6 |
| Clinical trials in South Korea | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
10 current trials in our China and South Korea registers name Biweekly (also registered as PCSK9 inhibitor) as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 7 of the 10 trials are recruiting: 6 with sites in China and 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Yun Dai Chen (2), Nanjing First Hospital, Nanjing Medical University (1), General Hospital of Shenyang Military Region (1) and Nanjing Medical University (1), among 9 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Biweekly works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Biweekly works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Biweekly (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.